

**PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM**  
**For biologic response modifier therapy: *Remicade (infliximab)***

Please fax form to:  
**1-866-840-1509**

Please note that the patient **AND** physician must complete this form. **All fields are mandatory and must be completed. Incomplete forms may result in your application being declined.** Please retain a copy of this form for your records.

**Instructions:**

- 1. PLEASE PRINT CLEARLY AND COMPLETE ALL SECTIONS.**
2. The patient/plan member must complete section A.
3. Your physician must complete section B. The cost, if any, of completing this form is at the expense of the patient/plan member.
4. Please return the form to your insurance company via Pharmacy Services at TELUS Health (a service provider of your insurance company) by fax to **1-866-840-1509**.
5. If you have any questions on the application of this program or the decision on reimbursement, or to inquire on the status of your Reimbursement Request Form, please contact your insurer.

<b>A. Information to be Completed by Patient</b>		
Employee or Insured's Name	Drug Card Number ____ - ____ - ____ - ____	
Patient's Name	Patient's Date of Birth (DD/MMM/YYYY) __ / __ / ____	Relationship to Employee/Insured <input type="checkbox"/> Employee <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent
<p><b>Please allow two business days for a response once all information is received and complete.</b>  <b>Notification of the results of this request will occur Monday to Friday between 9 am and 4 pm Eastern Time.</b></p>		

Please provide contact information and indicate **ONE** method of preferred contact for notification of the results:

<input type="checkbox"/> E-mail	<input type="checkbox"/> Call me (and leave a message if I'm not there)	<input type="checkbox"/> Fax me at:
<input type="checkbox"/> Contact my pharmacy: Pharmacy Name		Pharmacy Phone Number

I certify that the information provided by me is true, correct and complete to the best of my knowledge. I authorize my insurance company, TELUS Health (a service provider of my insurance company), their authorized representatives, agents and service providers to use and exchange this information needed for underwriting, administration and paying claims with any person or organization who has relevant information pertaining to this claim including health professionals, institutions and investigative agencies in the event of an audit. I authorize my insurance company and/or TELUS Health (a service provider of my insurance company) to contact any licensed physician, institution, pharmacy or person who has any records or knowledge of me or my health with respect to this submitted claim.

SIGNATURE OF PATIENT/PARENT/LEGAL GUARDIAN \_\_\_\_\_

Date: (DD/MMM/YYYY): \_\_ / \_\_ / \_\_\_\_

**PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM**  
**For biologic response modifier therapy: *Remicade (infliximab)***

Please fax form to:  
**1-866-840-1509**

**B. Information to be Completed by Prescribing Physician**

Drug Name	Strength	Dose
<b><i>Remicade (infliximab)</i></b>		

***Remicade (infliximab)* will be eligible for reimbursement only if the patient satisfies the conditions listed below and if the patient does not qualify for coverage under any other drug plan or government mandated program. If the patient is covered under another drug plan or government mandated program, the prior authorization program, as part of your drug benefits, may cover the portion not paid for by the primary plan. If “None of the above criteria” is indicated, the patient will not be eligible for reimbursement. For Quebec plan members, please refer to the RAMQ exception drug criteria, if applicable.**

**Eligibility Criteria**

Please indicate if the patient satisfies the following criteria:

- Ankylosing Spondylitis (AS; 9631008):
  - The patient:
    - Is  $\geq 18$  years of age; AND
    - Has a diagnosis of moderate to severe active AS, with a Bath AS Disease Activity Index (BASDAI) score  $\geq 4$  on 10 point scale; AND
    - Has tried and failed a trial of at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), each administered over a minimum 2-week period at maximum recommended/tolerated doses; AND
    - Is intolerant to, or had a confirmed adverse event with the subsequent entry biologic, Avsola, Inflectra or Renflexis (infliximab); AND
    - Has tried and failed one of: Simponi, Enbrel, Humira; AND
  - Physician is a rheumatologist or is experienced in the management of AS
  
- Adult Crohn’s Disease (34000006):
  - The patient:
    - Is  $\geq 18$  years of age; AND
    - Has a diagnosis of moderate to severe active Crohn’s Disease; AND
    - Has had an inadequate response to a corticosteroid and/or aminosalicylate; AND
    - Is intolerant to, or had a confirmed adverse event with the subsequent entry biologic, Avsola, Inflectra or Renflexis (infliximab); AND
    - Has tried and failed treatment with Humira; AND
  - Physician is a gastroenterologist or is experienced in the management of Crohn’s Disease
  
- Pediatric Crohn’s Disease (34000006):
  - The patient:
    - Is  $\geq 9$  years of age, AND  $< 18$  years of age
    - Has a diagnosis of moderate to severe active Crohn’s Disease; AND
    - Has had an inadequate response to a corticosteroid and/or aminosalicylate and/or an immunosuppressant; AND
    - Is intolerant to, or had a confirmed adverse event with the subsequent entry biologic, Avsola, Inflectra or Renflexis (infliximab); AND
  - Physician is a gastroenterologist or is experienced in the management of Crohn’s Disease
  
- For the treatment of patients with chronic Plaque Psoriasis (200965009):
  - The patient:
    - Is  $\geq 18$  years of age; AND
    - Has  $> 10\%$  Body Surface Area (BSA) involvement; OR
      - significant involvement of the face, hands, feet or genital regions; AND
    - Has a PASI score  $\geq 12$ ; OR
      - significant involvement of the face, hands, feet or genital regions; AND
    - Has failed to respond, is intolerant to, or unable to access UV phototherapy; AND

**PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM**  
**For biologic response modifier therapy: *Remicade (infliximab)***

Please fax form to:  
1-866-840-1509

**Eligibility Criteria**

- Has failed to respond, or has experienced a specific intolerance to, topical therapy and at least one systemic therapy; AND
- Is intolerant to, or had a confirmed adverse event with an infliximab biosimilar; AND
- Prescribing physician is a dermatologist or is experienced in the management of moderate-severe plaque psoriasis
  
- Psoriatic Arthritis (PsA; 156370009):
  - The patient:
    - Is  $\geq 18$  years of age; AND
    - Has a diagnosis of PsA with at least 3 swollen and 3 tender joints, and has stable plaque psoriasis with at least one lesion  $\geq 2$  cm in diameter; AND
    - Has tried and failed one or more disease-modifying anti-rheumatic drugs (DMARDs), AND
    - Is intolerant to, or had a confirmed adverse event with the subsequent entry biologic, Avsola, Inflectra or Renflexis (infliximab); AND
    - Has tried and failed one of: Simponi, Enbrel, Humira OR Cimzia; AND
  - Physician is a rheumatologist or is experienced in the management of PsA
  
- Rheumatoid Arthritis (RA; 69896004):
  - The patient:
    - Is  $\geq 18$  years of age; AND
    - Has a diagnosis of moderate to severe active RA; AND
    - Has tried and failed a minimum 12 week trial of Methotrexate plus one other disease modifying antirheumatic drug (DMARD). Where combinations of non-biologic DMARDs are impossible (a rare situation), consecutive non-biologic DMARDs would be acceptable; AND
    - Is intolerant to, or had a confirmed adverse event with the subsequent entry biologic, Avsola, Inflectra or Renflexis (infliximab); AND
    - Has tried and failed one of: Humira, Enbrel, Simponi, Actemra, Cimzia OR Orencia SC; AND
  - Physician is a rheumatologist or is experienced in the management of RA
  
- Adult Ulcerative Colitis (64766004):
  - The patient:
    - Is  $\geq 18$  years of age; AND
    - Has a diagnosis moderately to severely active ulcerative colitis (Mayo score 6 to 12 with endoscopic sub-score  $\geq 2$ ); AND
    - Has had an inadequate response to a corticosteroid and/or aminosalicylate and/or an immunosuppressant; AND
    - Is intolerant to, or had a confirmed adverse event with the subsequent entry biologic, Avsola, Inflectra or Renflexis (infliximab); AND
    - Has previously failed treatment with Humira; AND
  - Physician is a gastroenterologist or is experienced in the management of Crohn's Disease.
  
- Pediatric Ulcerative Colitis (64766004):
  - The patient:
    - Is  $\geq 6$  years of age, AND  $< 18$  years of age; AND
    - Has a diagnosis moderately to severely active ulcerative colitis (Mayo score 6 to 12 with endoscopic sub-score  $\geq 2$ ); AND
    - Has had an inadequate response to a corticosteroid and/or aminosalicylate and/or an immunosuppressant; AND
    - Is intolerant to, or had a confirmed adverse event with the subsequent entry biologic, Avsola, Inflectra, Renflexis (infliximab); AND
  - Physician is a gastroenterologist or is experienced in the management of ulcerative colitis.

OR

**PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM**  
**For biologic response modifier therapy: *Remicade (infliximab)***

Please fax form to:  
**1-866-840-1509**

**Eligibility Criteria**

None of the above applies

Relevant additional information \_\_\_\_\_

**Physician Information**

Physician's Name	License Number	Telephone Number	Fax Number	
Address		City	Province	Postal Code
Physician's Signature			Date: (DD/MMM/YYYY) ____ / ____ / ____	